このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

新たにMGMTメチル化IDH野生型神経膠芽腫と診断された患者における、放射線療法の有無にかかわらず、レゴラフェニブとテモゾロミドとの併用療法。 (REGOMA-2)

2026年11月3日 更新者:Istituto Oncologico Veneto IRCCS

新たにMGMTメチル化IDH野生型神経膠芽腫と診断された患者における、放射線療法の有無にかかわらず、レゴラフェニブとテモゾロミドとの併用療法。第I相用量決定研究

This study will evaluate the addition of regorafenib to standard of care treatment with TMZ as adjuvant therapy, and in combination with TMZ+RT as concomitant therapy.

The standard of care for newly diagnosed GBM (ndGBM) includes surgical resection to the extent that is safely feasible, followed by RT plus concomitant TMZ chemotherapy, and up to 6 months of adjuvant TMZ.

The dose escalation will be explored following a "3+3" design, escalating oral doses of regorafenib in combination with adjuvant (maintenance) TMZ (cohort A) to estimate the MTD of regorafenib as adjuvant (maintenance) therapy. After finding the MTD in the Adjuvant Therapy dose escalation, the Concomitant Therapy (cohort B) dose escalation will start, exploring escalating oral doses of regorafenib in combination with concomitant TMZ+RT, to estimate the MTD of regorafenib as concomitant therapy.

調査の概要

研究の種類

介入

入学 (実際)

21

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Padova、イタリア、35128
        • Istituto Oncologico Veneto IRCCS
      • Rozzano、イタリア、20089
        • Humanitas Research Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Males and females of ≥ 18 years of age at the time of signing the informed consent form (ICF).
  • Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
  • Patients capable of taking oral medication
  • Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  • Histologically confirmed Grade IV GBM/gliosarcoma (WHO criteria; non-IDH R132Hmutant by immunohistochemistry [IHC] or, sequencing for IDH1 and 2 in case of patients >55 years) established following either a radical or partial surgical resection. This includes treatment naïve (chemotherapy and RT) patients with prior histologically diagnosis of lower-grade astrocytoma that has been upgraded to a histologically verified glioblastoma after a subsequent definitive surgery.

NOTE: Patients with known isocitrate dehydrogenase (IDH) 1 and 2 are to be excluded.

  • Methylated MGMT according to local laboratory (in case of pyrosequencing, methylation >10%)

  • Subject must have recovered from the effects of surgery, including post-operative infections or complications. Toxicities resulting from surgery must have resolved to NCI CTCAE (v5.0) Grade ≤ 1 prior to starting regorafenib treatment (with the exception of Grade 2 alopecia).

  • For Concomitant Therapy Cohort: Prior tumor resection up to 7 weeks prior to the first dose of regorafenib.

  • For Adjuvant Therapy Cohort: Subject must have recently completed standard course of radiotherapy with TMZ chemotherapy, and then have an MRI documenting stable disease prior to the first dose of regorafenib (In case of "pseudoprogression" the patient will not be eligible)

  • For Adjuvant Therapy:

    1. All AEs resulting from prior RT+TMZ chemotherapy must have resolved to NCI CTCAE (v5.0) Grade 1 (except for laboratory parameters outlined below).
    2. Subject must have not experienced significant toxicity to prior RT+TMZ (i.e., Grade 4 hematological toxicity)
  • Subjects must have life expectancy of at least 6 months

  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 (or KPS 70)

  • Corticosteroid use of dexamethasone 4 mg or less per day within 7 days before starting regorafenib.

  • Subject must have the following laboratory values at screening within 7 days before starting regorafenib:

    1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if subject received pegfilgrastim).
    2. Hemoglobin (Hgb) ≥10 g/dL
    3. Platelet count (plt) ≥100x 109/L
    4. Serum potassium concentration within normal range, or correctable with supplements
    5. Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamate pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) ≤ 3.0 x Upper Limit of Normal (ULN).
    6. Serum total bilirubin ≤ 1.5 x ULN
    7. Serum creatinine ≤ 1.5 x ULN or measured glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m2 using an exogenous filtration marker such as iohexol, inulin, 51Cr EDTA or 1125 iothalamate, or creatinine clearance of ≥ 50 mL/min using Cockroft-Gault equation.
    8. Serum albumin > 3.5 g/dL
    9. PT (or INR) and APTT within normal range
  • For women who are not postmenopausal (i.e., < 2 years after last menstruation) or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, or barrier method of contraception in conjunction with spermicidal jelly) during the Treatment period and for at least 6 months after the last dose of study drug.

  • For male patients who are partners of premenopausal women: agreement to use a barrier method of contraception during the Treatment period and for at least 6 months after the last dose of study drug.

Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are eligible to participate.

Exclusion Criteria:

  • Received any prior treatment for glioma including:

    1. Prior prolifeprospan 20 with carmustine wafer.
    2. Prior intracerebral agent.
    3. Prior radiation treatment for GBM or lower-grade glioma.
    4. Prior chemotherapy or immunotherapy for GBM or lower-grade glioma.
    5. NOTE: 5-aminolevulinic acid-mediated photodynamic therapy and Flourcrescein administered prior to surgery to aid in optimal surgical resection is not considered a chemotherapy agent.
  • Patients who performed biopsy as surgical approach of glioblastoma.

  • Patients who are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort).

  • Patients who are receiving additional, concurrent, active therapy for GBM outside of the trial.

  • Disease located outside of the brain (e.g. brainstem and leptomeningeal disease).

  • Candidate for urgent palliative intervention for primary disease (e.g., impending herniation) as judged by the Investigator

  • History of allergy or hypersensitivity to any of the study treatments or any of their excipients.

  • In the presence of therapeutic intent to anticoagulate the patient: INR or PT and aPTT not within therapeutic limits (according to the medical standard in the institution). NOTE: Per American Society of Clinical Oncology (ASCO) guidelines, use of low-molecular-weight heparin (LMWH) should be the preferred approach.

  • Unable or unwilling to undergo brain MRI scans with intravenous (IV) gadolinium.

History of another malignancy in the previous 3 years, with a disease-free interval of< 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.

  • Serious, non-healing wound, ulcer, bone fracture, or abscess.
  • Any cerebrovascular accident (including transient ischemic attacks) within the last 6 months prior to initiation of study treatment.
  • Have an ongoing infection with severity of Grade 2 or above (CTCAE 5.0)
  • Any hemorrhage or bleeding event that is ≥ Grade 3 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE), Grade 2 intracranial hemorrhage, or persistent thrombotic/embolic event within 4 weeks prior to the start of study medication.
  • Uncontrolled or severe cardiac disease (e.g., history of unstable angina, myocardial infarction, coronary stenting, or bypass surgery within the last 6 months prior to initiation of study treatment), symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation), requirement for inotropic support or use of devices for cardiac conditions (e.g., pacemakers/defibrillators), or hypertension (participants with systolic blood pressure[BP] of > 160 mmHg or diastolic BP of > 100 mmHg despite optimal medical management are to be excluded).
  • History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or symptomatic pleural effusion.
  • Active, known, or suspected auto-immune disease, including systemic lupus erythematosus, Hashimotos thyroiditis, scleroderma, polyarteritis nodosa, or auto-immune hepatitis.
  • Known history of hepatitis B, human immunodeficiency virus (HIV), or active hepatitis C infection requiring treatment with antiviral therapy. Note: HIV testing is not required in the absence of clinical suspicion.
  • History of bleeding diathesis (irrespective of severity).
  • Uncontrolled intercurrent illness including (e.g., symptomatic ascites), but not limited to ongoing or active infection.
  • Persistent ≥ Grade 3 Lipase (> 2.0 - 5.0 x upper limit of normal [ULN] with signs or symptoms; > 5.0 x ULN and asymptomatic).
  • Persistent proteinuria> 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (≥ Grade 3, CTCAE 5.0)
  • Have any malabsorbition condition.
  • Any condition that could make the subject noncompliant with the study procedures and/or study requirements, as judged by the Investigator (for example: cognitive impairment, psychiatric illness, etc).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:コホート A (アジュバント/維持期)

Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.

Following a "3+3" design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.

In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy).

実験的:コホート B (併用相)

Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.

Following a "3+3" design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.

In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
用量制限毒性 (DLT) を患う患者の数
時間枠:用量漸増中の DLT 評価期間は、アジュバント相のサイクル 1 の 1 日目 (コホート A)、または併用 RT 相の 1 日目から最終日 (コホート B) までの 2 サイクルになります。 (各周期は28日です)
用量漸増中の DLT 評価期間は、アジュバント相のサイクル 1 の 1 日目 (コホート A)、または併用 RT 相の 1 日目から最終日 (コホート B) までの 2 サイクルになります。 (各周期は28日です)
Number of patients with ≥1 adverse event (AE) using the NCI CTCAE v5.0
時間枠:evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)
  • Grade 3 diarrhea, nausea, vomiting, and loss of appetite if lasting for ≥ 7 consecutive days;
  • Grade 3 electrolyte imbalance if lasting for ≥ 7 consecutive days;
  • Grade 3 dermal toxicity if lasting for ≥ 7 consecutive days;
  • Grade 3 fatigue for ≥ 7 consecutive days;
  • Grade 4 T-Bil, AST (GOT) and/or ALT (GPT) elevations,
evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)
Number of patients discontinuing study treatment due to an AE
時間枠:evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)

Number of patients discontinuing study treatment due to an AE

evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)

二次結果の測定

結果測定
メジャーの説明
時間枠
全生存
時間枠:放射線治療の開始から死亡まで、最大32か月まで評価
放射線治療の開始から死亡まで、最大32か月まで評価
Pharmacokinetics parameters - AUC
時間枠:evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)

area under the plasma concentration versus time curve

evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)
Best response to treatment according to RANO criteria
時間枠:from date of randomization until the date of first occurrence of disease progression or death, whichever come first,assessed up to 32 months

Tumor response according to RANO criteria

from date of randomization until the date of first occurrence of disease progression or death, whichever come first,assessed up to 32 months
Progression-free survival
時間枠:from the start of radiotherapy until the date of first occurrence of disease progression or death whichever come first,assessed up to 32 months

Survival time without tumor progression

from the start of radiotherapy until the date of first occurrence of disease progression or death whichever come first,assessed up to 32 months
EORTC QLQ-C30
時間枠:from the start of radiotherapy until the date of first occurrence of disease progression or death whichever come first,assessed up to 32 months

Survey with evaluations at screening, concurrently to brain MRI assessment and at the end of treatment

from the start of radiotherapy until the date of first occurrence of disease progression or death whichever come first,assessed up to 32 months
Pharmacokinetics parameters - Tmax
時間枠:evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)

Time to peak drug concentration

evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)
Pharmacokinetics parameters - Cmax
時間枠:evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)

Peak plasma concentration

evaluation period will be two cycles from Day -1 of Cycle 1 of adjuvant phase (cohort A) or from Day 1 to last day of the concomitant RT phase (Cohort B). (each cycle is 28 days)
Brain module BN20
時間枠:from the start of radiotherapy until the date of first occurrence of disease progression or death whichever come first,assessed up to 32 months

Survey with evaluations at screening, concurrently to brain MRI assessment and at the end of treatment

from the start of radiotherapy until the date of first occurrence of disease progression or death whichever come first,assessed up to 32 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年7月4日

一次修了 (実際)

2024年10月9日

研究の完了 (実際)

2025年12月22日

試験登録日

最初に提出

2023年3月10日

QC基準を満たした最初の提出物

2023年10月18日

最初の投稿 (実際)

2023年10月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年1月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する